Health Care Lobbying Surge Amid Trump Administration Scrutiny

Recent disclosures indicate that health industry firms and trade groups are significantly increasing their lobbying expenditures in Washington, D.C. The American Health Insurance Plans (AHIP) reported spending $5.3 million in the first quarter of 2026, marking its highest quarterly total on record. The Pharmaceutical Research and Manufacturers of America (PhRMA) followed closely with $12.2 million, the second-highest amount for any quarter, while the American Medical Association (AMA) spent nearly $8 million, its second-highest in the past decade. Notably, individual companies such as Eli Lilly, Gilead, Regeneron, and Humana also reported record lobbying expenditures during this period.

Politico

This surge in lobbying activity coincides with President Donald Trump's directive for Congress to advance his health care agenda, which includes codifying drug pricing deals and enhancing price transparency. The increased scrutiny of health care companies is part of an effort to counter Democratic criticisms regarding health care affordability ahead of the midterm elections.

Politico

The heightened lobbying efforts follow a tumultuous year for the health care sector, characterized by nearly $1 trillion in proposed Medicaid cuts under Trump's One Big Beautiful Bill Act and the expiration of enhanced Obamacare subsidies. Republican lawmakers have conducted hearings with health care executives to address these issues, while Centers for Medicare and Medicaid Services Administrator Mehmet Oz announced a nationwide crackdown on Medicaid fraud.

Politico

Chris Bond, an AHIP spokesperson, emphasized the group's commitment to advocating for consumer-focused solutions to improve health care affordability. Meanwhile, senior White House adviser Calley Means criticized K Street for impeding progress on Trump's agenda, highlighting the entrenched interests that resist change.

Politico

Trump's intervention in pharmaceutical pricing represents a significant shift for the Republican Party, traditionally seen as a pro-business entity. A health care lobbyist noted the unusual nature of a Republican administration actively challenging the pharmaceutical industry, which could disrupt established business models. Despite this, the health care sector has achieved notable policy victories, including a recent overhaul of pharmacy benefit managers' pricing practices.

Politico

Early earnings reports for the first quarter of 2026 reveal strong financial performance among major health care companies. UnitedHealth, the largest U.S. health insurer, raised its profit expectations following a challenging 2025, while Johnson & Johnson reported nearly a 10% increase in sales year-over-year.

Politico

Several lobbying firms are prominent in representing health care interests, including Todd Strategy Group, BGR Group, and Tarplin, Downs & Young for pharmaceutical companies, and Mehlman Consulting, Continental Strategy, and ALB Solutions for insurers. These firms are led by well-connected executives with extensive backgrounds in health policy and government.

Politico

While the health care industry is experiencing increased lobbying expenditures and legislative scrutiny, there is a lack of consensus on the long-term implications of these developments. The potential for further cuts to health care spending remains a contentious issue, with varying perspectives on the effectiveness of current lobbying efforts and the administration's policies.

Politico

• “I don’t see it slowing down probably until the end of this administration. That’s just not [Trump’s] style,” — Susan Zook, Founder, Mason Street Consulting

Politico

• “This town is built to make change very hard,” — Calley Means, Senior White House Adviser

Politico

• “It’s quite unusual where you have a Republican administration on full attack on the pharmaceutical industry, and in a way that would upend their entire business model,” — Anonymous Health Care Lobbyist

Politico